Pharmaceutical Business Review
Return to: PBR Home | Companies

Incyte Corp

Incyte Corp
1801 Augustine Cut-Off
Wilmington
United States of America
Phone: 1 302 4986700
Fax: 13-02-6365454
www.incyte.com

No. employees: 1,208
Turnover: 1,536.22 (US$m)
Financial year end: December

Company Overview

Top Competitors


Key Employees

Herve Hoppenot

Chief Executive Officer, President, Chairman, Executive Board

Julian C. Baker

Director, Non Executive Board

Paul A. Brooke

Director, Non Executive Board

Paul A. Friedman, M.D.

Director, Non Executive Board

Jean Jacques Bienaime

Director, Non Executive Board

Paul J. Clancy

Director, Non Executive Board

Jacqualyn A Fouse PhD

Director, Non Executive Board

Paula J. Swain

Executive Vice President - Human Resources, Senior Management

Reid M. Huber, Ph.D.

Executive Vice President, Chief Scientific Officer, Senior Management

Wenqing Yao, Ph.D.

Executive Vice President, Head of Discovery Chemistry, Senior Management

David W. Gryska

Chief Financial Officer, Executive Vice President, Senior Management

Steven H. Stein, M.D.

Chief Medical Officer, Senior Vice President, Senior Management

Barry P. Flannelly

Executive Vice President, General Manager - U.S., Senior Management

Vijay Iyengar, M.D.

Executive Vice President - Global Strategy and Corporate Development, Senior Management

Jonathan E Dickinson

Senior Vice President - Europe, General Manager - Europe, Senior Management

Lothar H Finke, MD, PhD

Head - Clinical Development, General Manager - Japan, Senior Management

Locations/Subsidiaries


1801 Augustine Cut-Off,
Wilmington,
Delaware,
United States of America
Phone: 1 302 4986700
Fax: 1 302 6365454

Incyte France SAS

France

Incyte Germany GmbH

Germany

Incyte Italy S.r.l.

Italy

Incyte Biosciences Luxembourg S.a r.l

6, rue Eugene Ruppert,
Luxembourg ,
Luxembourg

Incyte International Holdings Sarl

Luxembourg

Incyte Spain S.L.

Spain

Incyte Europe Sarl

Rue du Pre de la Bichette 1,
Geneva,
Genf,
Switzerland

Incyte Corporation Ltd

Carmelite 50 Victoria Embankment,
London,
United Kingdom

Incyte Holdings Corp

Wilmington,
Delaware,
United States of America

Products/Services


Products:

  • Jakafi (ruxolitinib)
  • Pipeline
  • Epacadostat (IDO1) :
  • Unresectable or Metastatic, Advanced Melanoma
  • NSCLC, Renal, Bladder, Head and Neck Cancer
  • Multiple Tumor Types
  • NSCLC, Bladder Cancer
  • Solid Tumors:
  • INCSHR1210 (PD-1, licensed from Hengrui)
  • INCAGN1876 (GITR)
  • INCAGN1949 (OX40)
  • PD-1 Platform Study
  • JAK1 Platform Study
  • Ruxolitinib (JAK1/JAK2):
  • Essential Thrombocythemia
  • Steroid-Refractory Acute GVHD
  • Itacitinib (JAK1):
  • Treatment-Naïve Acute GVHD
  • Non-Small Cell Lung Cancer
  • INCB52793 (JAK1): Advanced Malignancies
  • INCB50465 (PI3Kδ): DLBCL
  • INCB54828 (FGFR1/2/3):Bladder Cancer, Cholangiocarcinoma, 8p11 MPNs
  • Advanced Malignancies:
  • INCB54329 (BRD)
  • INCB57643 (BRD)
  • INCB53914 (PIM)
  • INCB59872 (LSD1): Acute Myeloid Leukemia, Small Cell Lung Cancer
  • INCB62079 (FGFR4): Hepatocellular Carcinoma

Services: